PDGFRB and mesothelioma: A clinical trial was launched to investigate the efficacy of vatalanib, a dual pan-VEGFR and platelet derived growth factor receptor (PDGFR)-β inhibitor in mesothelioma, and although the results showed minimal benefits, its low toxicity could warrant further experimentation to explore synergistic effects if combined with other standard treatments [16].